We are now a focused structural heart company which is where the real prize is. There is no question we have a real technological advantage in ADAPT which we now have in over 20 000 patients world wide.
Our scale is still small by standards but our competitive advantage will ensure we win the war in the future.
The real prize which is in a multi billion dollar space is TAVR and on that front we are advancing rapidly.
Now that we have divested the non core business of infusion and immunotherapies we can focus on the main game.
The journey is now well and truly underway (and far from over)
The best is yet to come.
Required sales, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.000(0.00%) |
Mkt cap ! $323.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 112 | $15.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.52 | 25 | 1 |
View Market Depth
| Last trade - 10.00am 20/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable